NDA 217673 · Insmed INC
Brinsupri
Brensocatib · Oral
NovelBreakthrough therapyPriority reviewCDER novel approval, Aug 12, 2025: To treat non-cystic fibrosis bronchiectasis
Last checked: Nov 19, 2026Latest source record: Aug 12, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Aug 12, 2025
Approved uses
1
Original approval plus efficacy supplements
Registered trials
18
2 Phase 3, 0 recruiting
FAERS reports
2,819
972 serious, 106 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 16, 2026.
BRINSUPRI is indicated for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult and pediatric patients 12 years of age and older. BRINSUPRI is a dipeptidyl peptidase 1 (DPP1) inhibitor indicated for the treatment of non-cystic fibrosis bronchiectasis in adult and pediatric patients 12 years of age and older. ( 1 )
Mechanism: Brensocatib is a competitive, reversible inhibitor of dipeptidyl peptidase 1 (DPP1). DPP1 activates pro-inflammatory neutrophil serine proteases (NSPs) during neutrophil maturation in the bone marrow. Activated NSPs are implicated in the pathogenesis of neutrophil-mediated NCFB inflammation. In cell-based assays, DPP1 inhibition by brensocatib reduces the activity of NSPs including neutrophil elastase, cathepsin G, and proteinase 3.
Therapeutic areas: Respiratory
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 12, 2025 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyLabelLetterReview
2 products under this application
- BRINSUPRI · BRENSOCATIB 25MG · TABLET, ORAL · Prescription
- BRINSUPRI · BRENSOCATIB 10MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Brensocatib" as an intervention, any sponsor and status, largest first.
- A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis BronchiectasisPivotal-lookingCompleted
Insmed IncorporatedIndustry
NCT04594369 · 1,767 participants · Start Dec 1, 2020 · Primary completion Oct 28, 2024
Drug: Brensocatib 10 mg; Brensocatib 25 mg and 1 more · For: Non-Cystic Fibrosis Bronchiectasis
Sites: Birmingham, Alabama; Conway, Arkansas; Little Rock, Arkansas · 373 sites in all
- STOP-COVID19: Superiority Trial Of Protease Inhibition in COVID-19Pivotal-lookingCompleted
University of DundeeAcademic, hospital or other
NCT04817332 · 406 participants · Start Jun 5, 2020 · Primary completion Feb 28, 2021
Drug: Brensocatib; Placebo · For: Covid19
Sites: Aberdeen, United Kingdom; Bath, United Kingdom; Birmingham, United Kingdom · 16 sites in all
- A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)Pivotal-lookingCompleted
Insmed IncorporatedIndustry
NCT06013241 · 288 participants · Start Oct 30, 2023 · Primary completion Sep 30, 2025
Drug: Brensocatib; Placebo and 1 more · For: Chronic Rhinosinusitis Without Nasal Polyps
Sites: Tucson, Arizona; Roseville, California; Upland, California · 100 sites in all
- Assessment of INS1007 in Participants With Non-Cystic Fibrosis BronchiectasisPivotal-lookingCompleted
Insmed IncorporatedIndustry
NCT03218917 · 256 participants · Start Oct 31, 2017 · Primary completion Dec 12, 2019
Drug: Brensocatib 10 mg; Brensocatib 25 mg and 1 more · For: Non-Cystic Fibrosis Bronchiectasis
Sites: Birmingham, Alabama; Peoria, Arizona; Newport Beach, California · 108 sites in all
- A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)Pivotal-lookingTerminated
Insmed IncorporatedIndustry
NCT06685835 · 214 participants · Start Dec 16, 2024 · Primary completion Feb 12, 2026
Drug: Brensocatib; Placebo · For: Hidradenitis Suppurativa
Sites: Phoenix, Arizona; Sacramento, California; Coral Gables, Florida · 72 sites in all
AstraZenecaAstraZeneca (AZN)
NCT02303574 · 89 participants · Start Dec 3, 2014 · Primary completion Aug 3, 2016
Drug: AZD7986, oral solution, 1 to 50 mg/mL; Placebo, oral solution · For: Safety, Pharmacokinetics, Pharmacodynamics, Food Effect
Sites: Harrow, United Kingdom
Insmed IncorporatedIndustry
NCT05927597 · 82 participants · Start Jan 9, 2019 · Primary completion Aug 1, 2019
Drug: INS1007; Placebo · For: Healthy Volunteers
Sites: Glendale, California
Insmed IncorporatedIndustry
NCT05355935 · 48 participants · Start Apr 27, 2022 · Primary completion Oct 7, 2022
Drug: Brensocatib; Moxifloxacin and 1 more · For: Healthy Volunteer
Sites: Madison, Wisconsin
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- therapy interrupted353
- cough300
- headache259
- dyspnoea204
- hospitalisation183
- product dose omission issue183
- pneumonia175
- rash174
- alopecia150
- dry skin146
- off label use146
- fatigue134
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2019 | 1 |
| 2020 | 1 |
| 2022 | 3 |
| 2023 | 7 |
| 2024 | 19 |
| 2025 | 268 |
| 2026 | 2,520 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis.
Chalmers JD, Burgel PR, Daley CL, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis.
Chalmers JD, Haworth CS, Metersky ML, et al. · N Engl J Med 2020 · Clinical Trial, Phase II, Multicenter Study
- Broad Immunomodulatory Effects of the Dipeptidyl Peptidase-1 Inhibitor Brensocatib in Bronchiectasis: Data from the Phase 2, Double-Blind, Placebo-controlled WILLOW Trial.
Johnson ED, Long MB, Perea L, et al. · Am J Respir Crit Care Med 2025 · Clinical Trial, Phase II, Randomized Controlled Trial
- Periodontal Effects of the Reversible Dipeptidyl Peptidase 1 Inhibitor Brensocatib in Bronchiectasis.
Gunsolley JC, Chalmers JD, Sibila O, et al. · JDR Clin Trans Res 2024 · Randomized Controlled Trial, Clinical Trial, Phase II
- The pharmacokinetics of brensocatib in participants with renal impairment following a single oral administration.
Yeung SA, Stein DS, Marbury TC, et al. · Br J Clin Pharmacol 2025 · Multicenter Study, Clinical Trial, Phase I
- Efficacy and safety of brensocatib in Japanese patients with non-cystic fibrosis bronchiectasis: Analysis of the ASPEN trial.
Morimoto K, Chalmers JD, Burgel PR, et al. · Respir Investig 2026 · Randomized Controlled Trial
Sponsor: Insmed INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.